Flagship Pioneering built the venture studio that gave the world Moderna. Now its playbook is running on orange trees in two hemispheres at once.
In a grove outside Lake Wales, Florida, a steel canister no larger than a fire extinguisher clamps onto the trunk of an orange tree. A needle pierces the bark, and over the next several minutes a measured dose of bactericide moves directly into the tree's vascular system: not sprayed onto leaves, not drenched into soil, but infused the way an IV line delivers medicine to a patient. The company behind the canister, Invaio Sciences, was built by Flagship Pioneering, the Cambridge, Massachusetts venture house whose most famous creation is a vaccine company that reshaped pandemic response. Flagship's newer wager is that the same precision-medicine logic used to engineer mRNA therapeutics can be pointed at a 19th-century bacterial disease now killing citrus trees from Florida to Sao Paulo state. In February 2026, that wager crossed an ocean, as Invaio signed a strategic collaboration with Fundecitrus, Brazil's citrus protection research fund, to begin testing and delivering its product candidates directly into Brazilian citrus trees under commercial conditions.
Huanglongbing, known as HLB or citrus greening, is not a new threat. The bacterial disease, first found in Florida in 2005, has spread rapidly across the state, attacking a tree's vascular system, limiting nutrient uptake, and ultimately reducing yield, fruit size, and quality while increasing tree mortality and the cost of production. The scale of what it has already done to one of America's signature agricultural industries is staggering. In the more than two decades the pathogen has been present in the state, Florida orange production has collapsed from 244 million 90-pound boxes in 1998 to just 12 million boxes for the 2024-25 season, a roughly 95 percent decline. A University of Florida survey of growers found that, on average, 90 percent of acres and 80 percent of trees in a Florida citrus operation are now HLB-infected, with growers attributing a 41 percent yield loss to the disease relative to pre-HLB levels.
The disease has not stayed contained to one state. Brazil is the world's largest orange producer, supplying roughly a third of global production and the majority of global juice supply, and in 2021 alone the country saw more than 17 million citrus trees uprooted because of HLB. Citrus greening has since made Brazil the new epicenter of the global crisis, with nearly half of the country's production now affected. For more than fifteen years, growers and regulators treated HLB as functionally untreatable: foliar sprays and soil drenches could suppress symptoms at the margins, but nothing reached the bacterium where it actually lived, deep in the tree's phloem.
Invaio's bet is that the failure was never about the chemistry. It was about delivery. As Gerardo Ramos, the company's Chief Scientific Officer and a veteran of senior R&D roles at Ciba-Geigy, Novartis, and Syngenta, has put it, spraying the standard bactericide oxytetracycline hydrochloride is inefficient because the chemical never reaches the tree's vascular system, where the disease actually spreads. Invaio's answer is a system called Trecise, which delivers a proprietary formulation called ArborBiotic directly into a tree's conductive tissue through a closed, minimally invasive mechanism, rather than spraying or drenching the surrounding environment.
The performance delta is the kind of number that gets a grower's attention. Unlike conventional injection treatments, the minimally invasive Trecise system requires 90 percent less active ingredient because it delivers directly into the tree's vascular system, and field trials have shown an average yield increase of 30 percent after just one treatment, alongside higher BRIX sugar content and reduced fruit drop. The system's 120-day pre-harvest interval is 60 days shorter than conventional injection treatments, and because it requires no drilling into the trunk, it can be used on young, non-bearing trees that previously had almost no viable treatment options.
That last point matters more than it might first appear. Growers who plant new trees in HLB-endemic regions have historically watched young, vulnerable trees succumb before they ever reach bearing age, discouraging replanting altogether. Dave Gerrard, Invaio's Head of Commercial US, explained the company's logic at the August 2023 launch: with an initial focus on treating young and non-bearing trees, the goal was to help growers get trees to bearing age with minimal disease symptoms and rebuild confidence in replanting in the first place. The solution received regulatory approval from the Florida Department of Agriculture and Consumer Services under section 24(c) of the Federal Insecticide, Fungicide and Rodenticide Act, and is approved for use on both bearing and non-bearing trees with a scion diameter between roughly 0.4 and 6 inches.
The closed-system design also addresses a problem that has dogged crop chemistry for decades: off-target exposure. Because Trecise applies active ingredients directly in the conductive tissues of the tree, it needs lower rates for equivalent efficacy, reducing the risks of misapplication and residues, while also dramatically reducing the risk of exposure to workers and the environment through its closed-system design.
What separates Invaio from the long line of agtech startups chasing citrus greening is its parentage. Invaio is not a standalone startup that raised venture money from Flagship; it is a company Flagship built from a hypothesis, the same model that produced Moderna. Invaio began as a Flagship Pioneering exploration in the summer of 2017, led by Barry Martin, a special agricultural advisor, and Ignacio Martinez, Invaio's founding CEO and a Flagship general partner, built around the idea that crop-damaging pests could be rendered harmless with tiny amounts of precisely delivered antimicrobials. The technical breakthrough came from cross-pollination with Flagship's biomedicine work: the firm was already building startups around exosomes, the tiny vesicles that carry proteins, DNA, and RNA between cells in human biology, and the Invaio team asked whether the same delivery logic could apply to plants, which use their own exosome-like systems as natural pathogen defenses.
The institutional machine behind that question is enormous. Since its 2000 launch, Flagship Pioneering has applied a hypothesis-driven innovation process through its Flagship Labs unit to originate more than 100 scientific ventures, resulting in over 100 billion dollars in aggregate value, deploying more than 2.9 billion dollars of its own capital alongside over 19 billion dollars of follow-on investment from other institutions. Ignacio Martinez, the executive who carried the citrus-greening thesis from a 2017 brainstorm to a commercial product, is a serial Flagship company-builder. He is co-founder and founding CEO of Montai Therapeutics, a founding team member and director at Indigo Ag, and the co-founder, founding CEO, and Chairman of CIBO Technologies, Inari Agriculture, and Invaio Sciences, having previously served as founding managing director of Syngenta Ventures, the corporate venture arm of the world's largest agrochemical company.
Invaio's own description of its R&D process leans directly on AI-driven drug discovery language rather than traditional crop science vocabulary. "We had the mode of action, the molecular delivery systems, the physical delivery systems," Martinez has said. "Now what we needed was AI to make sense of what could be possible." The company built powerful computational models, including a project on "digital trees" simulating the platform's possible impacts on plant biology and ecology before deploying it in the field.
In April 2024, Flagship installed a new CEO to run Invaio through its next phase: Amy O'Shea, who holds the title of CEO-Partner at Flagship while also serving as Invaio's chief executive, a structure that mirrors how Flagship manages leadership across its biomedicine portfolio. Noubar Afeyan, Flagship's founder and CEO and a co-founder of Invaio, described O'Shea as "uniquely positioned to bolster Flagship's efforts to transform agriculture and accelerate Invaio's growth trajectory as it delivers solutions that are better for farmers and for the planet."
Invaio's relationship with Brazil did not begin with the February 2026 announcement; it stretches back nearly five years, but the nature of the relationship has changed. Invaio first signed an agreement with Fundecitrus in May 2021 to evaluate a novel natural peptide called maSAMP, developed by Dr. Hailing Jin of the University of California, Riverside, and licensed to Invaio for global commercialization, in Brazilian field conditions. At the time, the work was explicitly preliminary. Avram Slovic, then Invaio's Senior Commercial Director of Latin America, said the goal of the collaboration was to bring the technology to Brazil and other citrus-growing regions already suffering from HLB, while cautioning that "these studies are preliminary."
Five years later, preliminary has given way to commercial. The February 2026 collaboration is explicitly designed to accelerate the development and evaluation of novel solutions, particularly peptide-based technologies, for controlling HLB, bringing together Invaio's Biologicals by Design platform and Fundecitrus' expertise in grove and pest management. The scientific obstacle the two organizations are jointly attacking is a genuinely strange one: the bacterium responsible for HLB cannot be grown in a laboratory dish at all. Because the bacterium responsible for HLB, Candidatus Liberibacter asiaticus, cannot be cultured in the laboratory, Fundecitrus has developed specialized assays and field-based methods to evaluate candidate solutions where traditional laboratory approaches simply do not work.
Crucially, the new agreement extends beyond research into the same precision-delivery hardware Invaio commercialized in Florida. Invaio will deploy its Trecise platform to test and deliver selected candidates directly into Brazilian citrus trees under commercial conditions, with Ricardo Miranda, Invaio's VP and Head of Global Development, framing Fundecitrus' scientific leadership as critical to advancing solutions that can transform how the disease is managed. Avram Slovic, now Invaio's Head of LatAm, said the company is "preparing to launch our first HLB solution in Brazil" and is "committed to expanding the arsenal of tools available to growers."
The stakes of getting this right in Brazil dwarf even the damage already inflicted on Florida. Brazil is currently the largest producer of oranges in the world, with 17 million tons of fruit produced annually, representing 21 percent of global production and supplying over 50 percent of global juice production, according to Peleg Chevion, Invaio's President and Chief Commercial Officer. A treatment system that works at Florida's scale is a Florida-sized solution. A treatment system that works at Brazil's scale is a global juice-supply solution.
Fundecitrus itself is not a startup or a government agency, but a grower-funded research institution with serious institutional weight. Founded 44 years ago in the state of Sao Paulo, the organization promotes the sustainable development of citrus production in Brazil through cutting-edge research facilities, hundreds of hectares of field trials in commercial orchards, and more than 130 staf…